Expert Interview
Discussing Novel Therapies in Dermatology with a focus on TYK2 in Psoriasis, IL-13 & OX-40(L) in Atopic Dermatitis and IL-17 in Hidradenitis Suppurativa
Ticker(s): REGN, BMY, AMGNInstitution: Harvard
- Assistant Professor of Dermatology at Harvard Medical School, Co-Leader of the Pathogens, Immunology, and Inflammation Translational Research Hub at Beth Israel & Director of the Clinical Laboratory for Epidemiology and Applied Research in Skin.
- Specializes in treating immune-mediated dermatologic conditions.
- Research interest includes Hidradenitis Suppurativa, Psoriasis, and Atopic Dermatitis with biologics and small molecules; leads both investigator-initiated and industry-sponsored clinical trials in these disease indications.
Roughly how many patients with psoriasis do you currently manage? With AD? With HS?
Added By: c_adminHow does oral IL-23 from J&J protagonist compare, and where do oral TYK2s fit in, especially with Deucra, Nimbus, and Vintix?
Will Skyrizi dominate the market in terms of safety, efficacy, and dosing convenience?
How will Stelara compare to Skyrizi in the future market?
What is the potential of topical treatments like Vtama vs. Zoryve in the dermatology landscape?
How will Dupi, Lebri, and other drugs shape the future of atopic dermatitis treatment?
Added By: catalin_adminWhat is the potential of topical JAK inhibitors, especially in comparison to new psoriasis topicals?
How will the landscape of psoriatic arthritis treatment evolve with the introduction of drugs like Cosentyx and Bimekizumab?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
